Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Connor P. Hall"'
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 22 (2022)
Pediatric high-grade gliomas (pHGGs) are aggressive diseases with poor outcomes. The diverse molecular heterogeneity in these rare tumors and inadequate tumor models have limited the development of effective therapies. In this issue of the JCI, Haase
Externí odkaz:
https://doaj.org/article/9e8cfadf48174eae8ecf6675c647436c
Purpose: The aim of our study is to evaluate the preclinical therapeutic activity and mechanism of action of BEZ235, a dual PI3K/mTOR inhibitor, in combination with dexamethasone in acute lymphoblastic leukemia (ALL).Experimental Design: The cytotoxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d432d3eda2f009a123441cb8e3ab4a9
https://doi.org/10.1158/1078-0432.c.6524789
https://doi.org/10.1158/1078-0432.c.6524789
Suppl Fig 2. BEZ235, Dexamethasone, and the combination effect on cell cycle.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fb161e5600740b69e0c07e165bfc560
https://doi.org/10.1158/1078-0432.22461440.v1
https://doi.org/10.1158/1078-0432.22461440.v1
Supplementary Table 1. Karyotype and PTEN mutational status and karyotype of B- and T-acute lymphoblastic leukemia/lymphoma cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5453531c34ef61ac707cdfcbfaf5d72
https://doi.org/10.1158/1078-0432.22461419
https://doi.org/10.1158/1078-0432.22461419
Suppl Fig 1. GC Receptor expression and functionality in T- and B-ALL cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3488280035b8f9c79b0a65d7068287ce
https://doi.org/10.1158/1078-0432.22461461
https://doi.org/10.1158/1078-0432.22461461
Suppl Fig 4. Effect on PI3K pathway. (A) AKT1 knockdown effect on BEZ235, dexamethasone, and BEZ235 plus dexamethasone cytotoxicity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ea14718219eb2aa4c0b8430076b2a55
https://doi.org/10.1158/1078-0432.22461434.v1
https://doi.org/10.1158/1078-0432.22461434.v1
Autor:
C. Patrick Reynolds, Timothy J. Triche, Daryl C. Drummond, Jonathan B. Fitzgerald, Winford Ko, Ashly Hindle, Riza E. Cruz, Ruben I. Calderon, Michael M. Song, Connor P. Hall, Nancy Paz, Joo-Sang Lee, Monish R. Makena, Jing Wang, Min H. Kang
Supplementary Figure 4: Inverse correlation between sensitivity to DNA damaging agents and SLFN11 expression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7b21ae371c0c68ae9097ecb6dd31713
https://doi.org/10.1158/1078-0432.22460978
https://doi.org/10.1158/1078-0432.22460978
Autor:
C. Patrick Reynolds, Timothy J. Triche, Daryl C. Drummond, Jonathan B. Fitzgerald, Winford Ko, Ashly Hindle, Riza E. Cruz, Ruben I. Calderon, Michael M. Song, Connor P. Hall, Nancy Paz, Joo-Sang Lee, Monish R. Makena, Jing Wang, Min H. Kang
Purpose: To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal irinotecan (nal-IRI).Experimental Design: Mouse plasma and tissue pharmacokinetics of nal-IRI and the current clinical formula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08cdeac6283876d09e8ace69f4c91b37
https://doi.org/10.1158/1078-0432.c.6524660
https://doi.org/10.1158/1078-0432.c.6524660
Suppl Fig 6. Mechanism of synergy of BEZ235 plus dexamethasone.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07cc1d7c265252872e1509acc57ee5fe
https://doi.org/10.1158/1078-0432.22461446.v1
https://doi.org/10.1158/1078-0432.22461446.v1
Autor:
C. Patrick Reynolds, Timothy J. Triche, Daryl C. Drummond, Jonathan B. Fitzgerald, Winford Ko, Ashly Hindle, Riza E. Cruz, Ruben I. Calderon, Michael M. Song, Connor P. Hall, Nancy Paz, Joo-Sang Lee, Monish R. Makena, Jing Wang, Min H. Kang
Supplementary Table 1. Human EFT, RMS, and NB cell lines used for current study. Supplementary Table 2. Median Survival of xenograft mice bearing human pediatric cancer treated with irinotecan or nal-IRI. Supplementary Table 3. Pharmacokinetic variab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::946b428e8b4f4a82a77b0d7a2b54b605
https://doi.org/10.1158/1078-0432.22460975
https://doi.org/10.1158/1078-0432.22460975